• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Halozyme to Acquire Elektrofi, Expanding Our Offerings in Innovative Drug Delivery and Strengthening Long-Term Growth into 2040s

    10/1/25 7:00:00 AM ET
    $HALO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $HALO alert in real time by email

    Royalty revenue contribution expected to begin as early as 2030

    Initial partner targets include derisked MoAs that are approved blockbusters today

    Highly scalable licensing model and long duration IP into 2040s; potential for individual product IP extension through proprietary reformulation

    Two of Elektrofi's partners projected to begin Hypercon™ formulated product clinical development by year end 2026, or earlier

    Halozyme to host conference call and webcast today at 5:30am PT/ 8:30am ET

    SAN DIEGO, Oct. 1, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme") today announced it has entered into a definitive agreement to acquire Elektrofi, Inc. ("Elektrofi"), a biopharmaceutical company with a breakthrough ultra-high concentration microparticle technology for biologics, branded Hypercon™. The transaction, which is comprised of an upfront payment of $750 million and up to three $50 million milestone payments contingent on three separate product regulatory approvals, was unanimously approved by the Boards of Directors of both Halozyme and Elektrofi.

    The Hypercon™ technology is an innovative microparticle approach that sets a new standard in the pursuit of hyper concentration, enabling high protein concentrations while maintaining syringeability, which is the ability to inject smoothly and easily. Hypercon™ enables biologic product formulation concentrations of 400-500 mg/ml, which can be up to 4 to 5 times higher than standard aqueous solution formulations for biologics today. The increased concentration reduces the volume of injection for the same dosage and will create more opportunities for at-home and HCP office delivery, including via small volume auto-injector or with Halozyme's innovative high volume auto-injector.

    "This acquisition marks a pivotal step in Halozyme's evolution. With Elektrofi's Hypercon technology, we are expanding and diversifying our drug delivery technology offerings to the biopharma industry and positioning Halozyme for continued long-term revenue growth through Elektrofi's licensing, royalty revenue business model," said Dr. Helen Torley, President and Chief Executive Officer of Halozyme. "We look forward to welcoming Elektrofi's talented team as we embark on our next chapter of drug delivery innovation to continue to drive value for all of our stakeholders including our partners, patients, and shareholders."

    Chase Coffman, Chief Executive Officer and Co-founder of Elektrofi, commented, "Since Elektrofi's founding, we have been committed to revolutionizing the delivery of biologic therapies so that patients can live life on their terms. Today's announcement brings us closer to achieving that vision. Halozyme's proven industry expertise and capabilities in developing drug delivery licensing businesses will advance our unique Hypercon technology, strengthen existing collaborations, support expansion into new partnerships and accelerate our commercialization strategy."

    Compelling Strategic Rationale

    Strong Strategic Fit:

    • Extends Halozyme's vision and breadth of innovative drug delivery technologies
      • Setting new standards in convenience, accessibility and treatment options with broad portfolio of first-to-market proprietary technologies
      • Complementary SC technologies support secular trend toward at-home and in healthcare practitioner office administration of biologics
      • Hypercon™ technology substantially expands scope of therapeutics that can be delivered subcutaneously with its ability to deliver highly concentrated biologics subcutaneously
    • Highly scalable licensing model with compelling expansion opportunities
      • Broad range of biologics programs and modalities creates meaningful opportunities across existing and new partners
      • Well aligned business models with royalty revenue and low capital intensity
    • Long duration intellectual property into 2040s
      • Supports long-term revenue growth opportunity
      • Enhances durability of drug delivery licensing business model

    Poised for Growth:

    • Expect near-term inflection and value creation
      • Initial partner products include de-risked MoAs that are approved blockbusters today
      • Two of Elektrofi's partners projected to begin Hypercon™ formulated product clinical development by year end 2026, or earlier
    • Clear pathway for significant growth beginning as early as 2030
      • Royalty revenues are projected to begin in 2030
      • Up to $275 million in potential development and commercial milestone payments from Elektrofi's existing two partner products expected to enter clinical development by year end 2026, or earlier, supports near-term de-risking of acquisition and low capital intensity of Elektrofi
    • Acquisition supports further de-risking and accelerated commercialization timeline of Hypercon™ technology
      • Leverages Halozyme's proven track record of developing, commercializing and scaling SC drug delivery technologies

    Financial Update

    The transaction is expected to be less than 5% dilutive to Non-GAAP diluted EPS over medium-term, excluding potential milestone payments related to programs in development, which could offset dilution prior to projected royalty revenue in 2030 and beyond. We expect full year 2026 incremental operating expense of approximately $55 million.

    Today, Halozyme is reaffirming its 2025 guidance ranges, which were last updated on August 5th, 2025, excluding the impact of the accounting treatment of the transaction. The final determination of whether this transaction will be accounted for as a business combination or asset acquisition will be determined at the close.

    For the full year 2025, the Company expects:

    • Total revenue of $1,275 million to $1,355 million, representing growth of 26% to 33% over 2024 total revenue, primarily driven by increases in royalty revenue. Revenue from royalties of $825 million to $860 million, representing growth of 44% to 51% over 2024.
    • Adjusted EBITDA1 of $865 million to $915 million, representing growth of 37% to 45% over 2024.
    • Non-GAAP diluted earnings per share1 of $6.00 to $6.40, representing growth of 42% to 51% over 2024. The Company's earnings per share guidance does not consider the impact of potential future share repurchases.

    Table 1. 2025 Financial Guidance





    Guidance Range





    Total Revenue



    $1,275 to $1,355 million





    Royalty Revenue



    $825 to $860 million





    Adjusted EBITDA 1



    $865 to $915 million





    Non-GAAP Diluted EPS1



    $6.00 to $6.40





    Transaction Details

    Under the terms of the agreement, Halozyme will acquire Elektrofi for $750 million in upfront consideration, financed by the Company's existing cash on its balance sheet and existing credit facility. The remaining consideration amount will be payable based on three contingent milestones for the successful marketing approvals of three HyperconTM products, valued at $50 million each.

    The Company expects its net leverage to be increased to approximately 2X net debt-to-EBITDA1 immediately following the transaction close and expects to rapidly de-lever in the subsequent quarters.  The transaction is expected to close in 4Q 2025, subject to completion of HSR review and other customary closing conditions.

    BofA Securities, Inc. is acting as financial advisor to Halozyme and Weil, Gotshal & Manges LLP is acting as legal advisor. Centerview Partners LLC is acting as financial advisor to Elektrofi and Morgan, Lewis & Bockius LLP is acting as legal advisor.

    1     Adjusted EBITDA and Non-GAAP Diluted EPS are Non-GAAP financial measures. See "Note Regarding Use of Non-GAAP Financial Measures" below for an explanation of these measures.

    Conference Call Details

    Halozyme will host a conference call and webcast today, Wednesday, October 1 at 5:30am PT/8:30am ET. The conference call may be accessed live with pre-registration via link: https://registrations.events/direct/Q4I781370. The call will also be webcast live through the "Investors" section of Halozyme's corporate website and a recording will be made available following the close of the call. To access the webcast and additional documents related to the call, please visit Halozyme.com.

    About Halozyme

    Halozyme is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. As the innovators of ENHANZE® drug delivery technology with the proprietary enzyme rHuPH20, Halozyme's commercially-validated solution is used to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid subcutaneous delivery and reduced treatment burden. Having touched one million patient lives in post-marketing use in ten commercialized products in at least one major region and across more than 100 global markets, Halozyme has licensed its ENHANZE® technology to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, argenx, ViiV Healthcare, Chugai Pharmaceutical and Acumen Pharmaceuticals.

    Halozyme also develops, manufactures and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technologies that are designed to provide commercial or functional advantages such as improved convenience, reliability and tolerability, and enhanced patient comfort and adherence. The Company has two commercial proprietary products, Hylenex® and XYOSTED®, partnered commercial products and ongoing product development programs with Teva Pharmaceuticals and McDermott Laboratories Limited, an affiliate of Viatris Inc.

    Halozyme is headquartered in San Diego, CA and has offices in Ewing, NJ and Minnetonka, MN. Minnetonka is also the site of its operations facility.

    For more information visit www.halozyme.com and connect with us on LinkedIn and Twitter.

    About Elektrofi

    Elektrofi is a biopharmaceutical formulation technology company that is revolutionizing the delivery of biologic therapies by giving patients the ability to control how they want to receive and benefit from life-changing medicines. Its breakthrough hyper concentrated microparticle technology, HyperconTM, resolves the limitations associated with intravenously delivered biologic therapies by enabling convenient at-home subcutaneous self-administration. With a focus on monoclonal antibodies, therapeutic proteins, and other large molecule drugs, they create, develop, and commercialize subcutaneous biologic therapies in collaboration with strategic partners. Elektrofi believes a patient-centered healthcare approach can lead to a healthier world.  The company is headquartered in Boston and innovates globally.

    Note Regarding Use of Non-GAAP Financial Measures

    In this press release we provide guidance with respect to measures not considered to be in accordance with generally accepted accounting principles ("Non-GAAP") measures, such as adjusted earnings before interest, taxes, depreciation, and amortization ("Adjusted EBITDA") and Non-GAAP diluted earnings per share. These measures are in addition to, and not as a substitute for, or superior to, financial measures calculated in accordance with GAAP. The Company calculates Non-GAAP diluted earnings per share excluding share-based compensation expense, amortization of debt discounts, intangible asset amortization, one-time items, if any, such as changes in contingent liabilities, inventory adjustments, impairment charges and intellectual property litigation costs, and certain adjustments to income tax expense. The Company calculates Non-GAAP diluted shares excluding the dilutive impact of convertible notes which is used in calculating Non-GAAP diluted earnings. The Company calculates EBITDA excluding interest, taxes, depreciation and amortization. The Company calculates adjusted EBITDA excluding one-time items, if any, such as changes in contingent liabilities, inventory adjustments, impairment charges, transaction costs for business combinations and intellectual property litigation costs. The Company does not provide reconciliations of forward-looking adjusted measures to GAAP due to the inherent difficulty in forecasting and quantifying certain amounts that are necessary for such reconciliation, including adjustments that could be made for changes in share-based compensation expense and the effects of any discrete income tax items. For the same reasons, the Company is unable to address the probable significance of the unavailable information. The Company provides Non-GAAP financial measures that it believes will be achieved; however, it cannot accurately predict all of the components of the adjusted calculations and the GAAP measures may be materially different than the Non-GAAP measures.

    Forward-Looking Statements

    In addition to historical information, the statements set forth in this press release include forward-looking statements including, without limitation, statements concerning the Company's expected future financial performance and growth rates (including the Company's  2025 financial guidance and the assumptions used in deriving such guidance) including expectations for future total revenues, collaboration and royalty revenues,  adjusted EBITDA and non-GAAP diluted EPS, future plans, objectives, expectations and intentions relating to a potential transaction concerning Elektrofi, such potential transaction's expected impact and contributions to the Company's, Elektrofi's and the combined group's operations and financial results (including potential development and commercialization of partnered products and timing related to these events), the financing and closing of such potential transaction, as well as the expected timing and benefits of such potential transaction, the Company's and Elektrofi's future product development and regulatory events and goals, and product collaborations.  Forward-looking statements regarding the Company's ENHANZE® drug delivery technology include the possible benefits and attributes of ENHANZE® including its potential application to aid in the dispersion and absorption of other injected therapeutic drugs and facilitating more rapid delivery and administration of higher volumes of injectable medications through subcutaneous delivery and potential to decrease treatment burden and enable new treatment sites.  Forward-looking statements regarding Elektrofi's Hypercon™ technology include statements regarding its ability to achieve certain levels of biologic concentration and enable the administration of smaller volumes or doses of pharmaceutical products.  Forward-looking statements related to Elektrofi's intellectual property include expectations for length of patent terms and patent expirations and the expected impact such patents may have on the duration, durability and amounts of future royalty payments the Company may receive from licensing such intellectual property.  Forward-looking statements regarding the combined group's business may also include potential growth driven by the combined group's partner development and commercialization efforts (including anticipated product approvals and launches and the timing related to these events), anticipated royalty terms and rates for the Company's current and future collaboration products and product candidates, projections for future sales revenue and market share of the combined group's collaborators' products and product candidates, potential new or expanded collaborations, collaborative targets and indications for partnered products.  These forward-looking statements are typically, but not always, identified through use of the words "expect," "believe," "enable," "may," "will," "could," "can," "durable," "growth," "innovate," "develop," "vision,"  "potential," "intends," "estimate," "anticipate," "plan," "predict," "probable," "potential," "possible," "should," "continue," and other words of similar meaning and involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Actual results could differ materially from the expectations contained in these forward-looking statements as a result of several factors, including uncertainties concerning future matters such as market conditions, changes in domestic and foreign business, changes in the competitive environment in which the Company and Elektrofi operate, and financing a potential transaction, inability of the parties to successfully or timely consummate a transaction, including the risk that any required regulatory approvals are not obtained, are delayed or are subject to unanticipated conditions that could adversely affect the combined group or the expected benefits of a transaction, unexpected levels of the combined group's revenues, expenditures and costs, unexpected results or delays in the growth of the combined group's business, or in the development, regulatory review or commercialization of the combined group's partnered or proprietary products, unexpected early expiration or termination of the patent terms for the combined group's drug delivery technologies,  unexpected levels of revenues (including royalty revenue received from the combined group's collaboration partners and revenues from proprietary product sales), expenditures and costs, unexpected results or delays in the growth of the combined group's business (including as a result of unexpected conversion rates) or other proprietary product revenues, or in the development, regulatory review or commercialization of the combined group's partnered products, regulatory approval requirements, unexpected adverse events or patient outcomes and competitive conditions. These and other factors that may result in differences are discussed in greater detail in the Company's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission, including under the headings "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations".  Except as required by law, the Company undertakes no obligation to update or revise any forward-looking statements or any other information contained herein.

    Contact

    Tram Bui

    Halozyme

    VP, Investor Relations and Corporate Communications

    609-359-3016

    [email protected]

    Halozyme Therapeutics, Inc. Logo. (PRNewsFoto/Halozyme Therapeutics, Inc.) (PRNewsfoto/Halozyme Therapeutics, Inc.)

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/halozyme-to-acquire-elektrofi-expanding-our-offerings-in-innovative-drug-delivery-and-strengthening-long-term-growth-into-2040s-302571888.html

    SOURCE Halozyme Therapeutics, Inc.

    Get the next $HALO alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $HALO

    DatePrice TargetRatingAnalyst
    8/6/2025$75.00Equal-Weight → Overweight
    Morgan Stanley
    7/10/2025$55.00Neutral
    Goldman
    5/14/2025$62.00Overweight → Equal-Weight
    Morgan Stanley
    5/13/2025$47.00Market Perform → Underperform
    Leerink Partners
    10/7/2024$58.00 → $62.00Overweight → Equal Weight
    Wells Fargo
    9/19/2024$52.00 → $57.00Overweight → Neutral
    JP Morgan
    6/7/2024$48.00 → $51.00Overweight → Neutral
    Piper Sandler
    2/29/2024$54.00Outperform
    TD Cowen
    More analyst ratings

    $HALO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Halozyme Therapeutics upgraded by Morgan Stanley with a new price target

    Morgan Stanley upgraded Halozyme Therapeutics from Equal-Weight to Overweight and set a new price target of $75.00

    8/6/25 7:53:02 AM ET
    $HALO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Goldman resumed coverage on Halozyme Therapeutics with a new price target

    Goldman resumed coverage of Halozyme Therapeutics with a rating of Neutral and set a new price target of $55.00

    7/10/25 8:55:45 AM ET
    $HALO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Halozyme Therapeutics downgraded by Morgan Stanley with a new price target

    Morgan Stanley downgraded Halozyme Therapeutics from Overweight to Equal-Weight and set a new price target of $62.00

    5/14/25 8:56:30 AM ET
    $HALO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $HALO
    SEC Filings

    View All

    Halozyme Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure

    8-K - HALOZYME THERAPEUTICS, INC. (0001159036) (Filer)

    10/1/25 7:06:21 AM ET
    $HALO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 10-Q filed by Halozyme Therapeutics Inc.

    10-Q - HALOZYME THERAPEUTICS, INC. (0001159036) (Filer)

    8/5/25 4:09:53 PM ET
    $HALO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Halozyme Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - HALOZYME THERAPEUTICS, INC. (0001159036) (Filer)

    8/5/25 4:06:09 PM ET
    $HALO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $HALO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SVP, CHIEF FINANCIAL OFFICER Labrosse Nicole sold $173,584 worth of shares (2,227 units at $77.95), decreasing direct ownership by 9% to 22,079 units (SEC Form 4)

    4 - HALOZYME THERAPEUTICS, INC. (0001159036) (Issuer)

    9/23/25 4:15:01 PM ET
    $HALO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SVP, CHIEF FINANCIAL OFFICER Labrosse Nicole exercised 12,406 shares at a strike of $12.11 and sold $1,514,267 worth of shares (20,000 units at $75.71), decreasing direct ownership by 24% to 24,306 units (SEC Form 4)

    4 - HALOZYME THERAPEUTICS, INC. (0001159036) (Issuer)

    9/11/25 5:09:57 PM ET
    $HALO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    PRESIDENT AND CEO Torley Helen sold $4,444,626 worth of shares (60,000 units at $74.08) and exercised 60,000 shares at a strike of $8.11 (SEC Form 4)

    4 - HALOZYME THERAPEUTICS, INC. (0001159036) (Issuer)

    9/4/25 5:41:27 PM ET
    $HALO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $HALO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Halozyme to Acquire Elektrofi, Expanding Our Offerings in Innovative Drug Delivery and Strengthening Long-Term Growth into 2040s

    Royalty revenue contribution expected to begin as early as 2030 Initial partner targets include derisked MoAs that are approved blockbusters today Highly scalable licensing model and long duration IP into 2040s; potential for individual product IP extension through proprietary reformulation Two of Elektrofi's partners projected to begin Hypercon™ formulated product clinical development by year end 2026, or earlier Halozyme to host conference call and webcast today at 5:30am PT/ 8:30am ET SAN DIEGO, Oct. 1, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme") today announced it has entered into a definitive agreement to acquire Elektrofi, Inc. ("Elektrofi"), a biopharm

    10/1/25 7:00:00 AM ET
    $HALO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Halozyme to Participate at Upcoming Investor Conferences

    SAN DIEGO, Aug. 28, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme") today announced that Dr. Helen Torley, President and Chief Executive Officer, and Tram Bui, VP of Investor Relations and Corporate Communications, are scheduled to participate and host investor meetings at the following investor conferences.  Details on the Company's participation are as follows: Event: 2025 Wells Fargo Healthcare Conference Format: Fireside Chat and 1x1 Meetings Presentation Date: Thursday, September 4, 2025 Presentation Time: 10:30am PT / 1:30pm ET Location: Boston, MA Event: Morgan Stanley 23rd Annual Global Healthcare Conference Format: Fireside Chat and 1x1 Meetings Date: Mon

    8/28/25 8:30:00 AM ET
    $HALO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    HALOZYME RAISES 2025 FINANCIAL GUIDANCE RANGES AND REPORTS STRONG SECOND QUARTER 2025 RESULTS

    Total Revenue Increased 41% YOY to $326 million and Royalty Revenue Increased 65% YOY to $206 million Net Income Increased 77% YOY to $165 million; Adjusted EBITDA Increased 65% YOY to $226 million; GAAP Diluted EPS Increased 85% YOY to $1.33; Non-GAAP Diluted EPS Increased 69% YOY to $1.541 Raising 2025 Financial Guidance Ranges for Total Revenue to $1,275 - $1,355 million, Representing YOY Growth of 26% - 33%, Adjusted EBITDA to $865 - $915 million, Representing YOY Growth of 37% - 45% and Non-GAAP Diluted EPS to $6.00 - $6.40, Representing YOY Growth of 42% - 51%1 Announcing Third $250 million Share Repurchase Tranche Under $750 million Authorized Plan  SAN DIEGO, Aug. 5, 2025 /PRNewswir

    8/5/25 4:01:00 PM ET
    $HALO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $HALO
    Leadership Updates

    Live Leadership Updates

    View All

    KaliVir Immunotherapeutics Appoints Schond Greenway as Chief Financial Officer

    KaliVir Immunotherapeutics, Inc., a biotech company developing cutting-edge, multi-mechanistic oncolytic viral immunotherapy programs, today announces the appointment of Schond Greenway as Chief Financial Officer (CFO). With more than 25 years of experience in corporate finance and investment analysis, Mr. Greenway has extensive biotechnology expertise, notably in navigating capital markets and spearheading successful fundraising initiatives. "We are thrilled to welcome Schond as our inaugural CFO. As we advance into clinical development with our lead program VET3-TGI, his proven track record in biotech finance and strategic leadership will be pivotal in steering KaliVir through our next

    9/4/24 8:00:00 AM ET
    $AVTX
    $DRRX
    $HALO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Medicinal Chemicals and Botanical Products

    Mahesh Krishnan Elected to Halozyme's Board of Directors

    SAN DIEGO, April 25, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme") today announced the election of Mahesh Krishnan, M.D. to its Board of Directors. Dr. Krishnan has more than 20 years of experience in healthcare, biotechnology and health services. "Mahesh is a dynamic and highly accomplished healthcare executive, and we are pleased to welcome him to the Halozyme board," said Dr. Helen Torley, president and chief executive officer. "His experience with building and growing business opportunities in addition to his medical expertise, will provide valuable perspective as we expand our leadership as the premier provider of innovative drug delivery technologies." Dr.

    4/25/24 4:45:00 PM ET
    $HALO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Halozyme Appoints Barbara Duncan to its Board of Directors

    SAN DIEGO, Feb. 6, 2023 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme") today announced the appointment of Barbara Duncan to its Board of Directors. Ms. Duncan brings more than 25 years of experience as a financial executive with significant leadership roles in the biopharmaceutical industry. "We are delighted to welcome a leader with Barbara's extensive biopharmaceutical industry and finance experience to the Halozyme board," said Dr. Helen Torley, president and chief executive officer. "Barbara's business leadership, financial expertise and board experience will add important insights and contributions to the continuing success and growth of the company." Ms. Duncan

    2/6/23 8:30:00 AM ET
    $HALO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $HALO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Halozyme Therapeutics Inc.

    SC 13G/A - HALOZYME THERAPEUTICS, INC. (0001159036) (Subject)

    11/12/24 9:36:57 AM ET
    $HALO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Halozyme Therapeutics Inc.

    SC 13G - HALOZYME THERAPEUTICS, INC. (0001159036) (Subject)

    10/17/24 9:36:19 AM ET
    $HALO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by Halozyme Therapeutics Inc. (Amendment)

    SC 13G/A - HALOZYME THERAPEUTICS, INC. (0001159036) (Subject)

    2/13/24 5:06:13 PM ET
    $HALO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $HALO
    Financials

    Live finance-specific insights

    View All

    Halozyme to Acquire Elektrofi, Expanding Our Offerings in Innovative Drug Delivery and Strengthening Long-Term Growth into 2040s

    Royalty revenue contribution expected to begin as early as 2030 Initial partner targets include derisked MoAs that are approved blockbusters today Highly scalable licensing model and long duration IP into 2040s; potential for individual product IP extension through proprietary reformulation Two of Elektrofi's partners projected to begin Hypercon™ formulated product clinical development by year end 2026, or earlier Halozyme to host conference call and webcast today at 5:30am PT/ 8:30am ET SAN DIEGO, Oct. 1, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme") today announced it has entered into a definitive agreement to acquire Elektrofi, Inc. ("Elektrofi"), a biopharm

    10/1/25 7:00:00 AM ET
    $HALO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    HALOZYME RAISES 2025 FINANCIAL GUIDANCE RANGES AND REPORTS STRONG SECOND QUARTER 2025 RESULTS

    Total Revenue Increased 41% YOY to $326 million and Royalty Revenue Increased 65% YOY to $206 million Net Income Increased 77% YOY to $165 million; Adjusted EBITDA Increased 65% YOY to $226 million; GAAP Diluted EPS Increased 85% YOY to $1.33; Non-GAAP Diluted EPS Increased 69% YOY to $1.541 Raising 2025 Financial Guidance Ranges for Total Revenue to $1,275 - $1,355 million, Representing YOY Growth of 26% - 33%, Adjusted EBITDA to $865 - $915 million, Representing YOY Growth of 37% - 45% and Non-GAAP Diluted EPS to $6.00 - $6.40, Representing YOY Growth of 42% - 51%1 Announcing Third $250 million Share Repurchase Tranche Under $750 million Authorized Plan  SAN DIEGO, Aug. 5, 2025 /PRNewswir

    8/5/25 4:01:00 PM ET
    $HALO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Halozyme to Report Second Quarter 2025 Financial and Operating Results

    SAN DIEGO, July 22, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme") today announced it will release its second quarter 2025 financial and operating results on Tuesday, August 5, 2025, following the close of trading. Halozyme will host a conference call on Tuesday, August 5, 2025 at 1:30 p.m. PT/4:30 p.m. ET to discuss the results. The conference call may be accessed live with pre-registration via this link https://registrations.events/direct/Q4I78137779. A live webcast and replay of the conference call will also be available through the "Investors" section of Halozyme's corporate website at www.halozyme.com. About Halozyme Halozyme is a biopharmaceutical company a

    7/22/25 8:30:00 AM ET
    $HALO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care